

# **Interferon- $\gamma$ signaling in eosinophilic esophagitis has implications for epithelial barrier function and programmed cell death.**

Megha Lal, PhD<sup>1</sup>, Caitlin M. Burk, MD<sup>2</sup>, Ravi Gautam, PhD<sup>1</sup>, Zoe Mrozek, BS<sup>1</sup>, Tina Trachsel, MD<sup>1,3,4</sup>, Jarad Beers, MS<sup>1</sup>, Margaret C. Carroll, BS<sup>1</sup>, Duncan M. Morgan, PhD<sup>5</sup>, Amanda B. Muir, MD<sup>6,7</sup>, Wayne G. Shreffler MD, PhD<sup>2,8</sup>, Melanie A. Ruffner, MD, PhD<sup>1,7,\*</sup>

<sup>1</sup>Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, USA

<sup>2</sup>Food Allergy Center and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA

<sup>3</sup>Division of Allergy, University Children's Hospital Zurich, Zurich, Switzerland

<sup>4</sup>Division of Allergy, University Children's Hospital Basel, Basel, Switzerland

<sup>5</sup>Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT); Department of Chemical Engineering, MIT, Cambridge, MA, USA

<sup>6</sup>Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, USA

<sup>7</sup>Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania

<sup>8</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA

\*Corresponding author: Melanie A. Ruffner, [ruffnerm@chop.edu](mailto:ruffnerm@chop.edu)

# ABSTRACT

**Objective:** Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disorder characterized by eosinophil-rich mucosal inflammation and tissue remodeling. Transcriptional profiling of esophageal biopsies has previously revealed upregulation of type I and II interferon (IFN) response genes. We aim to unravel interactions between immune and epithelial cells and examine functional significance in esophageal epithelial cells.

**Design:** We investigated epithelial gene expression from EoE patients using single-cell RNA sequencing and a confirmatory bulk RNA-sequencing experiment of isolated epithelial cells. The functional impact of interferon signaling on epithelial cells was investigated using *in vitro* organoid models.

**Results:** We observe upregulation of interferon response signature genes (ISGs) in the esophageal epithelium during active EoE compared to other cell types, single-cell data, and pathway analyses, identified upregulation in ISGs in epithelial cells isolated from EoE patients. Using an esophageal organoid and air-liquid interface models, we demonstrate that IFN- $\gamma$  stimulation triggered disruption of esophageal epithelial differentiation, barrier integrity, and induced apoptosis via caspase upregulation. We show that an increase in cleaved caspase-3 is seen in EoE tissue and identify interferon gamma (IFNG) expression predominantly in a cluster of majority-CD8<sup>+</sup> T cells with high expression of *CD69* and *FOS*.

**Conclusion:** These findings offer insight into the interplay between immune and epithelial cells in EoE. Our data illustrate the relevance of several IFN- $\gamma$ -mediated mechanisms on epithelial function in the esophagus, which have the potential to impact epithelial function during inflammatory conditions.

## Key Messages:

### What is already known about this topic:

- The transcriptome of esophageal biopsy tissue reproducibly distinguishes eosinophilic esophagitis from histologically normal tissue, with evidence of mixed inflammatory signals.
- Interferon response signature genes are elevated in EoE biopsy tissue compared to controls, suggesting T1 in addition to T2 cytokine signaling within EoE mucosa.

### What this study adds:

- We observe reproducible, robust upregulation of interferon signature genes in esophageal epithelium, and we confirm that esophageal epithelium expresses functional IFN- $\alpha$  and IFN- $\gamma$  receptors.
- IFN- $\gamma$  treatment of epithelial organoids has several detrimental effects, including decreased proliferation, organoid formation, and increased caspase activation.
- Analysis of single-cell RNA-sequencing data from of EoE biopsy tissue during active disease and remission identified that a CD8<sup>+</sup> population expressing high levels of *FOS*, *ITGAE*, and *ITGA1* expresses high levels of *IFNG*

### How this study might affect research, practice, or policy:

- We identify esophageal epithelium as the cellular source for interferon response gene signature in EoE and a CD8<sup>+</sup> tissue-resident memory T-cell population was the main source of *IFNG*.
- Further mechanistic studies are required to identify how non-T2 signaling mechanisms like IFN- $\gamma$  signaling contribute to EoE pathogenesis, and if this pathway can be targeted as an adjunctive therapy for EoE.

# INTRODUCTION

EoE is a chronic allergic disorder of the esophagus characterized by eosinophil-rich mucosal inflammation and epithelial barrier dysfunction (1–5). Strong evidence links type 2 (T2) cytokine signaling to mucosal inflammation in EoE, including the presence of pathologic effector T cells in esophageal mucosal during active disease (6–9). The recent successful clinical trials of dupilumab, a monoclonal antibody targeting the IL4R $\alpha$  subunit of IL-4 and IL-13 receptors, highlight the importance of T2 signaling in EoE (3).

Despite the strong link between T2-cytokine-mediated inflammation and EoE, prior research indicates that IFN signaling is upregulated during EoE(10, 11). Sayej *et al.* measured increased IFN- $\gamma$  production from EoE biopsy cultures (11). We previously reported that interferon gene signatures (ISG) are upregulated in biopsy tissue from adults and children with EoE (10). This was recently replicated in a large reanalysis of 137 EoE patient biopsy transcriptomes (12).

Here, we utilize complementary datasets to interrogate IFN signaling in EoE. We use single-cell RNA sequencing to examine IFN production and responses in esophageal mucosal cell populations. Within this dataset, we observe heterogeneity of ISG expression, and identify upregulation of ISG within epithelial cells compared to other cell clusters. We confirm the upregulation of ISG in RNA-sequencing of epithelial cells isolated from esophageal biopsies of EoE patients. IFN- $\gamma$  signaling has previously been shown to decrease epithelial barrier function and induce apoptosis in epithelial cells of the airway, intestine, and skin (13–17). Here, we hypothesized that IFN- $\gamma$  signaling would result in similar effects in esophageal epithelium and utilized organoid models to examine organoid morphology, epithelial function, and transcriptional responses following interferon treatment. This work offers insight into immune-epithelial crosstalk in EoE and demonstrates potential mechanisms of IFN- $\gamma$ -mediated esophageal epithelial barrier dysfunction.

# METHODS

## Biopsy single-cell RNA-sequencing

Data from Morgan *et al.* (8) was accessed in NCBI GEO database (8, 18, 19) using accession number [GSE175930](#), and analyzed in Seurat using R as described (8, 20–23). The dataset includes 14,242 cells (10,049 active, 4,193 remission) with over 500 unique genes. T/NK cell dataset included 4423 cells with 900 unique genes each (3066 active, 1409 remission). After normalization, variable gene selection and scaling, UMI and percent mitochondrial genes were regressed prior to principal component analysis and UMAP visualization using the top 10 components. Clusters from Morgan *et al.* were used for further analysis (8) to examine interferon response signature genes previously identified in patients with EoE (10). Differential expression was evaluated (FindMarkers), reporting average log2-fold change and adjusted p-values (Bonferroni corrected). Dot and volcano plots were generated with the R packages, dittoSeq 1.11.0 (24) and EnhancedVolcano 1.16.0 (25), respectively.

## Esophageal biopsy specimens

The studies were approved by the institutional review board of Partners Healthcare (GSE175930) and Children's Hospital of Philadelphia (GSE234973). Participants or their legal guardians provided written informed consent prior to study participation.

Esophageal biopsies for the esophageal epithelial whole sample RNA-seq study were collected during routine clinical endoscopy (Table S1). Subjects met EoE diagnostic criteria (26), with active EoE defined by symptoms of esophageal dysfunction and  $\geq 15$  eosinophils/high-power microscopic field on biopsy tissue. Control subjects underwent endoscopy due to clinical symptoms, but esophageal and distal histology demonstrated no abnormalities. Patients with celiac disease, inflammatory bowel disease, gastrointestinal bleeding, immunodeficiency, or recent immunomodulator use were not eligible to participate in this study.

## **Primary esophageal epithelial cell isolation**

Esophageal biopsies were dissociated (27) and CD45+ cells were removed using positive isolation beads (STEMCELL TECHNOLOGIES). The untouched epithelial-enriched cell fraction was washed with PBS, lysed in Tri Reagent, then total RNA was extracted by column purification (PicoPure™ RNA Isolation Kit, Thermo Fisher Scientific).

## **Esophageal epithelial cell culture**

Telomerase-immortalized human esophageal keratinocytes EPC2-hTERT(28) were grown in keratinocyte-SFM (KSFM) containing 0.09mM Ca<sup>2+</sup>, 1ng/ml rEGF, 1ng/ml bovine pituitary extract and 10,000 U/mL Penicillin-Streptomycin. High calcium KSFM media (1.8 mM Ca<sup>++</sup>) was used to induce epithelial maturation for 48 hours (i.e., flow cytometry, apoptosis assay, and MTT assay) prior to stimulation with cytokines. IFN- $\alpha$  (Fisher Scientific) and IFN- $\gamma$  (Sigma-Aldrich) were added to culture media in varying concentrations, as indicated.

## **Flow cytometry**

EPC2-hTERT cells were dissociated, resuspended, then stained for viability (Zombie NIR™, Biolegend) in PBS for 15min in FC Block (BD Biosciences). 1x10<sup>6</sup> cells then stained in 200  $\mu$ L on ice for 30 minutes with: Alexa Fluor® 405 anti-IFN $\alpha$ / $\beta$  R1 (1 $\mu$ g, FAB245V, R&D Systems), PE anti-IFN $\alpha$  R2 (1 $\mu$ g, AB\_2898715, Invitrogen), Alexa Fluor® 488 anti-IFN $\gamma$  R1/CD119 (1 $\mu$ g, FAB6731G, R&D Systems) and APC anti-IFN $\gamma$  R2 (0.5 $\mu$ g, FAB773A, R&D Systems). LSR-Fortessa and FlowJo software (BD Biosciences) were used for analysis.

## **Western Blot**

8  $\mu$ g of protein was resolved on 10% SDS-PAGE, then transferred to a 0.2 $\mu$ m PVDF, blocked then incubated overnight at 4°C in primary antibody (rabbit anti-human STAT1 1:500, HPA000931, Sigma-Aldrich; mouse anti-human pSTAT1 1:1000, 33-3400, Invitrogen; mouse anti-human STAT2, 1:2500, MAB1666, clone 545117, R&D; rabbit anti-human pSTAT2, 1:1250, PA5-78181, Invitrogen). Membranes were washed then

incubated for 1 hour at room temperature with secondary antibody (Goat Anti-Mouse Starbright Blue 520 and Goat Anti-Rabbit Starbright Blue 700, each at 1:2500, Bio-Rad). Blots were analyzed (ChemiDoc™ MP Imaging System, Bio-Rad) and quantified using Image Lab software.

### **3D organoid cell culture**

Esophageal organoids were cultured as described (27, 29). Briefly,  $2 \times 10^3$  EPC2-hTERT cells were mixed in 50µl of Matrigel (Corning®) and seeded into a 24-well plate, then cultured 500µl of high  $\text{Ca}^{2+}$  KSFM 11 days. Organoids were treated with IFN- $\alpha$  (Fisher Scientific) or IFN- $\gamma$  (Sigma-Aldrich) on days 7 and 9. Organoid number, size, and formation rate (OFR) were determined from phase contrast images of organoids (BZ-X710 Fluorescence Microscope, Keyence). OFR was defined as the average number of  $\geq 50$  µm spherical structures at Day 11 divided by the total number of cells seeded in each well at day 0 (29). Organoids were isolated for downstream analysis using vigorous pipetting and vortexing in DPBS (Gibco) to dissociate them from the Matrigel matrix.

Organoids were paraffin-embedded (32), sectioned, and stained for hematoxylin and eosin (H&E) or immunohistochemistry (IHC) analyses. Basaloid cell content was determined from H&E stained organoids by calculating the total height of both basaloid cell layers divided by overall organoid diameter and expressed as a percentage (29). The average basaloid content was calculated using four measures per organoid. For IHC, organoid sections were incubated with anti-human pSTAT1 (1:200, 9167L, Cell Signaling Technology), anti-human Ki67 (1:200, ab16667, Abcam), anti-human IVL (1:20000, I9018-0.2ML, Sigma-Aldrich), anti-human CLDN1 (1:500, LS-C415827, LS-BIO), and anti-human OCLN (1:200, ab216327, Abcam). Semi-quantitative analysis was performed in ImageJ software (NIH) using a minimum of 10 organoids per group.

For gene expression analysis, day 11 organoids treated with IFN $\alpha$  200U/ml (Fisher Scientific), IFN- $\gamma$  5ng/ml (Sigma-Aldrich), and IL-13 10ng/ml (Sigma-Aldrich) were isolated, washed, and lysed in Tri Reagent. RNA was extracted for sequencing using RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol.

## **Bulk RNA sequencing and data analysis**

RNA libraries of esophageal epithelial tissue biopsies and organoids were prepared using SMART-Seq HT Ultra Low Input RNA kit (Clontech) and NEBNext Ultra II RNA Library Prep Kit for Illumina, respectively. Paired-end sequencing was performed on Illumina HiSeq 2500 and generated data was deposited in NCBI GEO (18, 19) under accession numbers GSE234973 and GSE234424. Sequencing quality was assessed with FastQC 0.14.1 (30) and MultiQC 1.10 (31). Trimmomatic 0.39 (32) trimmed low-quality reads and removed adapters, followed by pseudo-alignment and quantification against GRCh38.p13 using kallisto 0.46.0 (33). Low-abundance genes were filtered, and weighted trimmed mean of M-values (TMM) normalization was performed using edgeR 3.38.4 (34). Principal component analysis (PCA) was performed using base R and differential gene expression was analyzed using limma 3.52.4 (35). Facilitated Gene set enrichment analysis (GSEA) was performed with clusterProfiler 4.4.4 (36, 37) using MSigDB (38, 39). A list of 429 genes with 4-fold elevated expression in the esophagus (esophageal-specific genes) was obtained from the Human Protein Atlas (accessed on August 11, 2022) (40). Heatmaps and interaction network plots were created using gplots 3.1.3 (41) and Cytoscape 3.9.1 (42). Statistical plots and other data visualizations were generated using the R package ggplot2 3.4.0 (43), unless otherwise stated.

## **Air-liquid interface (ALI) culture**

Cells were seeded on a 0.4µm transwell (Corning®) in 300µl of low-calcium KSFM as previously described (44). Cultures were grown in high calcium media beginning day 3, then on day 7 upper chamber media was removed. IFN-α (Fisher Scientific) and IFN-γ (Sigma-Aldrich) treatments were performed from day 10 to 14.

## **Transepithelial electrical resistance (TEER)**

Net ALI membrane resistance for each sample was determined by measuring the sample resistance with a MillicellERS-2 Voltohmmeter (Merck Millipore) then subtracting the blank sample resistance reading. TEER values ( $\Omega \cdot \text{cm}^2$ ) were calculated as net



resistance \* membrane area (0.33cm<sup>2</sup> for 24-well inserts, Millipore). Only samples with TEER > 200 Ω\*cm<sup>2</sup> on day 10 were used for stimulation experiments.

### **FITC-Dextran Permeability Assay**

70kDa fluorescein isothiocyanate-dextran (FITC dextran; 3mg/ml; Sigma-Aldrich) was added to apical chambers and then incubated at 37°C for 4 hours. Basolateral chamber media was transferred into a clean 96-well plate and fluorescence levels were determined to assess flux.

### **Caspase activity assays**

Epithelial cells were matured, treated with cytokines, then incubated with 100μl of the caspase loading solution (1:200) for 60min. Caspase-3 and caspase-8 activity were determined using a fluorometric multiplex activity assay kit (Abcam) according to the manufacturer's instructions. Fluorescence was measured at Ex/Em=535/620nm for caspase-3 and Ex/Em=490/525nm for caspase-8.

### **MTT assay**

Epithelial cells (1×10<sup>4</sup>/well) were cultured in 96-well plates, matured in high calcium media, treated with cytokines, then incubated with 0.5mg/ml MTT solution at 37°C for 3 hours. Cells were spun down at 2500rpm for 5min, then resuspended in 100μL of DMSO while shaking for 15 minutes at 300rpm. The absorbance was measured at 562nm.

## **RESULTS**

### **Esophageal epithelium expresses interferon response signature in EoE.**

To identify cell types contributing to the interferon gene signature (IGS) observed in EoE biopsy gene expression data, we analyzed phenotypic clusters (Figure S1) generated by Morgan et al (8), that used samples from 6 patients with active EoE and 4 in remission. We used IGS from our prior work to examine gene expression across all cell types (Figure

S2), observing the highest number of differentially regulated ISGs in epithelium (Figure 1A) compared to other cells (Figure S3).

To validate this finding, we isolated epithelial cells from patients with EoE and non-EoE controls (Table 1, patient demographics), and performed bulk RNA sequencing to analyze the epithelial-specific transcriptome in EoE. Analogous to findings in EoE whole-biopsy tissue (10, 12, 45, 46), unsupervised hierarchical clustering differentiates epithelial cell samples from active EoE biopsies from non-EoE controls (Figure S4 and Figure 1B). In epithelial-enriched samples from active EoE, we identified 523 differentially expressed genes (DEGs) compared to controls ( $FDR < 0.05$  and  $\log_2FC \geq |1|$ , Figure 1C and Table S2), with 265 upregulated and 258 downregulated. Upregulated DEGs included *CCL26* (47), *ALOX15* (48), *LRRC31* (49), *POSTN* (50), *TNFAIP6* (51), *KRT32* (52), and *CRISP3* (51), which have been previously implicated in the immunopathology of EoE.

Gene set enrichment analysis identified *IFN- $\gamma$  response* (NES = 2.12, p.adjust = 2.12E-03) as the most significant upregulated pathway, followed by *TNF- $\alpha$  signaling by NF $\kappa$ B* (NES = 1.93, p.adjust = 8.63E-03), inflammatory response (NES = 1.91, p.adjust = 8.63E-03), *IFN $\alpha$  response* (NES = 1.90, p.adjust = 1.32E-02), and a cell-cycle related pathway, *E2F targets* (NES = 1.93, p.adjust = 8.63E-03) (Figure 1D, Figure S5 and Table S3). A gene-pathway interaction network analysis (Figure 1E) indicated *TNFAIP6*, *RTP4*, *ICAM1*, *IRF1*, *NMI*, and *TAP1*, were shared across IFN- $\gamma$  response, TNF- $\alpha$  signaling by NF $\kappa$ B, inflammatory response, and IFN- $\alpha$  response pathways. There was a leading-edge overlap between the IFN- $\gamma$  and IFN- $\alpha$  pathways, but no overlap genes in the E2F targets and other pathways.

### **IFN- $\gamma$ treatment reduces epithelial organoid formation and alters morphology.**

Given this evidence of pathway overlap, we next assessed the impact of interferon signaling on immortalized human esophageal keratinocytes, EPC2-hTERT (28). Flow cytometry confirmed interferon receptor expression in EPC2-hTERT (Figure 2A, gating strategy Figure S6). Western blot analysis demonstrated increase pSTAT-1 and pSTAT-2 following INF- $\gamma$  and IFN- $\alpha$  treatment (Figure 2B), respectively, confirming functional receptor signaling.

Subsequently, we examined the effect of IFN- $\alpha$  and IFN- $\gamma$  stimulation in the esophageal epithelial organoid model, due to its ability to reproduce the proliferation and differentiation gradient of the esophageal epithelium in humans (29). EPC2-hTERT esophageal keratinocytes in organoid culture were treated with IFN- $\alpha$  or IFN- $\gamma$  on days 7 and 9 (Figure 2C). We observed decreased organoid formation rate in IFN- $\alpha$  200U/ml ( $18.27 \pm 1.26$  %, p-value < 0.01), IFN- $\alpha$  400U/ml ( $15.53 \pm 0.76$  %, p-value < 0.001) as well as IFN- $\gamma$  5ng/ml ( $17.7 \pm 0.29$  %, p-value < 0.001) and IFN- $\gamma$  10ng/ml ( $17.93 \pm 0.38$ %, p-value < 0.001) groups (Figure 2D). Similarly, organoid size was significantly reduced following treatment with IFN- $\alpha$  400U/ml ( $110.27 \pm 8.41$   $\mu$ m, p-value < 0.001) as well as IFN- $\gamma$  5ng/ml ( $111.44 \pm 8.23$   $\mu$ m, p-value < 0.001) and IFN- $\gamma$  10ng/ml ( $113.47 \pm 16.29$   $\mu$ m, p-value < 0.01) (Figure 2E). Both IFN- $\gamma$  and IFN- $\alpha$  display dose-dependent loss of central epithelial differentiation (Figure S7) but this was more pronounced with IFN- $\gamma$  5ng/ml and 200U/ml concentrations, respectively (Figure 2F). Further analysis of organoids treated with IFN- $\alpha$  200U/ml and IFN- $\gamma$  5ng/ml revealed increased basaloid content in IFN- $\gamma$  treated organoids ( $20.54 \pm 3.64$  % vs.  $15.08 \pm 2.50$ , p-value < 0.01), suggesting accumulation of outer, less-differentiated basaloid cell layers (Figure 2G). Staining for Ki67 showed a decrease at day 7 in IFN- $\gamma$  treated organoids (p < 0.001), correlating with the strongest signal in the expression of pSTAT1 in all IFN-treated organoids (p < 0.001, Figure S8 and Figure 2H). There was a modest increase in IVL staining at day 7 in both IFN- $\alpha$  (p < 0.001) and IFN- $\gamma$  treated groups (p < 0.01), consistent with earlier maturation in the interferon-treated samples.

### **IFN- $\gamma$ treated organoids mimic EoE epithelial gene expression signature.**

We used RNA-sequencing to examine transcriptional responses of IFN- $\gamma$  and IFN- $\alpha$  treated organoids. Unsupervised sample clustering differentiated IFN- $\gamma$  treated organoids from IFN- $\alpha$  and control groups (Figure 3A). We identified 1448 downregulated genes and 1859 upregulated genes in IFN- $\gamma$  treated organoids at FDR < 0.05 and  $\log_2\text{FC} \geq |1|$  (Figure 3B). In contrast, we detected 30 DEGs in IFN- $\alpha$  treated organoids at FDR < 0.05 and  $\log_2\text{FC} \geq |1|$  (Figure S9, and Table S4). IFN- $\gamma$  treated organoids share 27 upregulated and 97 downregulated transcripts with epithelium from EoE patients (Figure S10), more closely mimicking EoE patients' epithelial gene expression than IFN- $\alpha$  treated

organoids. This holds true with more permissive FDR thresholds for additional analysis of the IFN- $\alpha$  associated gene signature.

We investigated the impact of interferon signaling on esophageal-specific transcription using a dataset of esophagus-specific genes from the Human Protein Atlas (429 transcripts with >4-fold higher expression in the esophagus than other human tissues, Table S5) (53). We observed 74 (17.25%) upregulated and 103 (24%) downregulated DEGs overlapping between IFN- $\gamma$  treated organoids with esophageal-specific genes (Figure 3D, Table S6). These genes are associated with a range of biological processes, including apoptosis, cell adhesion, and differentiation, suggesting IFN- $\gamma$  treatment alters transcriptional regulation of pathways critical for epithelial cell proliferation, survival, and barrier function. We next tested the hypothesis that IFN- $\gamma$  and IL-13 treatment result in distinct patterns of esophageal gene expression. We examined DEGs from IFN- $\gamma$  treated and IL-13 treated organoids (54). Only 32 esophageal-specific genes are regulated by both IFN- $\gamma$  and IL-13, implying that impacts of IFN- $\gamma$  and IL-13 on esophageal-specific genes are largely distinct (Figure S11 and Table S7). Of these, 23 (71.8%) are downregulated. Gene set enrichment analysis of IFN- $\gamma$  treated organoid DEGs identified 14 pathways with positive and 10 with negative enrichment scores (Figure 3D, Table S8)

### **IFN- $\gamma$ treatment disrupts the epithelial barrier in the esophageal epithelium.**

IFN- $\gamma$  has been shown to contribute to epithelial barrier dysfunction within the intestine (55–60), and impaired barrier function is known to play a crucial role in EoE (61, 62). Our transcriptional analyses revealed positive enrichment of the HALLMARK\_APICAL\_JUNCTION gene set in IFN- $\gamma$  treated organoids (Figure 3C, NES= 1.58, adj.p= 1.74E-02). Although 41 genes in this pathway are upregulated in the IFN- $\gamma$  treated organoids (Figure 4A), there is decreased protein expression for claudin 1 and occludin in IFN- $\gamma$  treated organoids (Figure 4B) consistent with prior reports of IFN- $\gamma$ -induced tight junction disruption (56, 63, 64).

We utilized the air-liquid interface culture (ALI) model (Figure 4C) to examine the effect of interferon treatment on esophageal epithelial barrier function. IFN- $\gamma$  treatment decreased transepithelial electrical resistance (TEER) 3-fold in 5ng/ml and 10 ng/ml

conditions (p-value < 0.05, Figure S12 and Figure 4D). Similarly, para-cellular permeability to 70 kDa FITC-Dextran increased after treatment with IFN- $\gamma$  5ng/ml and 10 ng/ml (p-value < 0.05 and <0.01, respectively, Figure 4E).

### **IFN- $\gamma$ treatment upregulates caspase expression in esophageal epithelium.**

The HALLMARK\_APOPTOSIS gene set was positively enriched in IFN- $\gamma$  treated organoids (Figure 3C, NES= 1.88, adj.p = 9.65E-04), and IFN- $\gamma$  treated samples clustered separately from the other treatment conditions (Figure 5A), with upregulation of pro-apoptotic genes, including *PMAIP1*, *CASP7*, *TNFSF10*, *BCL2L1*, and *GADD45B*. To validate these findings, we examined caspase activity in EPC2-hTERT esophageal epithelial cells after 24 hours of IFN treatment in vitro. Caspase-3 and Caspase-8 activity were significantly increased in IFN- $\gamma$  treated epithelial cells (Figure 5B, p-value < 0.001), accompanied by decreased cell viability with the highest concentration of IFN- $\alpha$  assessed (400U/ml, p-value < 0.001) and at all IFN- $\gamma$  concentrations tested (p-value < 0.001). To assess the potential relevance of apoptosis in EoE, we stained esophageal biopsy tissue for activated caspase-3. We observed increased staining for activated caspase-3 in a cytoplasmic distribution scattered through the epithelium of EoE samples (Figure 5D).

### **Single-cell analysis reveals activated CD8+ T cells express *IFNG*.**

To determine which cells expressed interferons signaling genes, we examined the phenotypic clusters generated by Morgan et al. (8) as shown in Figure S1. Scaled expression frequency of *IFNG* in each cluster revealed enrichment in T cells (Figure 6A). In contrast, *IFNA* transcripts were not detected in the dataset, and *IFNL* transcripts were detected at low levels in <10% of all cells (data not shown). IFN- $\gamma$  receptor subunits, *IFNGR1* and *IFNGR2*, were expressed by several cell types, with the highest expression observed in eosinophils and neutrophils (Figure 6A).

To examine *IFNG* expression in T cells, we next interrogated T cell subsets using T cell cluster annotations as presented by Morgan et al. in Figure S13. This revealed that *IFNG* was expressed by a cluster of activated CD8+ T cells (Trm2) (Figure 6B). This cluster exhibited features consistent with activated tissue resident CD8+ memory cells,

showcasing high enrichment in CD69 and FOS, and relative enrichment in CD103 (*ITGAE*) and CD49a (*ITGA1*) (Figure S13).

## DISCUSSION

In this study, we used complementary esophageal epithelial datasets to interrogate interferon signaling in EoE patients. We use scRNA-seq of EoE patients (6 with active EoE and 4 in remission) to identify that the epithelium has robust interferon signature gene (ISG) expression (Figure 1A), and to identify a CD8<sup>+</sup> cell cluster with upregulated *IFNG* expression. RNA-sequencing analysis of esophageal epithelial cells isolated from biopsy tissue (Figures 1B-1E) confirmed ISGs as the most highly upregulated pathways. Using the esophageal organoid model, we demonstrate that IFN- $\gamma$  treatment disrupts epithelial proliferation, decreases organoid formation and size, and causes abnormal morphology. IFN- $\gamma$  treatment decreased epithelial barrier function in the air-liquid interface model and induced apoptosis *in vitro*.

Recent studies have highlighted that EoE is not exclusively a T2-driven disorder but has mixed pathophysiology (12). Esophageal epithelium has been shown to respond to multiple signaling mechanisms that are relevant in EoE, including cytokines (7, 9, 65), innate signaling molecules (44), and metabolites (54). Prior studies have identified elevated levels of IFN- $\gamma$  expression in EoE patients (66, 67), *IFNG*<sup>+</sup> T cells in EoE mucosa (68). Prior studies in EoE have shown that ISG is upregulated and conserved in both children and adults with EoE (12, 45). In contrast, transcriptional studies in atopic dermatitis have revealed T2 and T17 signature among all age groups but T1 cytokine signatures primarily in adults (69, 70). Future studies that quantitate mucosal cytokine expression in EoE would help to determine a precise understanding of the balance of cytokine signals that impact esophageal epithelium during this disorder, leading to more sophisticated models and therapies.

Dysregulated IFN- $\gamma$  signaling has been shown to contribute to increased intestinal permeability (14, 16, 17). These studies implicate IFN- $\gamma$ -induced epithelial dysfunction via several mechanisms, which, to the best of our knowledge have not been examined in the

esophageal epithelium. Our data demonstrate IFN- $\gamma$  has detrimental effects on epithelial barrier function, as evidenced by decreased TEER and increased FITC-dextran permeability (Figure 4D and 4E). We observed a decrease in claudin 1 and occludin expression, consistent with prior reports of downregulation following IFN- $\gamma$  exposure (64, 71). Further, we observe pronounced disruption of the typical proliferation timeline in IFN- $\gamma$  treated organoid cultures, with decreased Ki67 on day 7, and significantly diminished OFR and size. Overall, this suggests that IFN- $\gamma$  can have profound impact on esophageal epithelial function.

Our analysis of data from IFN- $\gamma$  treated organoids indicated IFN- $\gamma$  regulates 41% of esophageal-specific genes (Figure 3D). Classification based on biological processes revealed these affect apoptosis, cell adhesion, differentiation, and keratinization. IFN- $\gamma$  has been shown to induce epithelial apoptosis in epithelial cells from other tissues (72–76), and we observed enrichment of apoptosis pathways IFN- $\gamma$  treated organoid samples (Figure 5A). IFN- $\gamma$  treatment induced caspase-3 and caspase-8 activity and cell death in esophageal epithelial cells. While increased epithelial apoptosis is not classically considered a finding of EoE, we observed increased cleaved caspase-3 staining in active EoE biopsy tissue samples. Skin lesions in atopic dermatitis, characterized by a mixed T2 high inflammatory infiltrate, have also been shown to have increased activated caspase-3 in keratinocytes(77, 78). Interestingly, in atopic dermatitis the degree of apoptosis has been correlated with dermal IFN- $\gamma$  expressing CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes.

Prior studies have suggested that T cells may be a source of IFN- $\gamma$  in the esophageal tissue of EoE patients. Wen *et al.* investigated 1088 individual T cells from EoE patients and control patients using scRNA-seq and reported *IFNG* expression in 84% of T cells (68). Sayej *et al.* reported that cultured biopsies from EoE patients had higher expression of TNF- $\alpha$  and IFN- $\gamma$ , particularly in CD3<sup>+</sup>CD8<sup>+</sup> but not in CD3<sup>+</sup>CD4<sup>+</sup> T cell populations (11). Here, we identify *IFNG*-expression in a T cell cluster with characteristics consistent with CD8<sup>+</sup> Trm given expression of CD8 subunits, *FOS*, CD103 (*ITGAE*), and CD49a (*ITGA1*) (79, 80). Our data indicate that these cells have similar level of *IFNG* expression in active and inactive EoE, suggesting they may maintain a more activated



state even during inactive EoE. Apart from the CD8<sup>+</sup> cluster, we observed modest expression of *IFNG* in the endothelium (Figure 6C). We did not detect meaningful levels of *IFNA* or *IFNL* in any cell clusters. It is possible that our gene expression studies failed to detect low levels of transcript expression that could be meaningful at the protein level. For example, recent data suggests the esophageal epithelium may produce IFN- $\gamma$  *in vitro* (81). However, questions remain about role of interferon expression during EoE. Additional work to correlate the spatial organization of interferon expression in CD8<sup>+</sup> cells with the epithelium could help determine if the ISGs signature in epithelium is related to proximity to CD8<sup>+</sup> cells. The overall role of CD8<sup>+</sup> cells during EoE is largely unknown, and examining these cells during active disease and remission may yield additional insight into the pathophysiology of EoE.

In summary, we provide evidence that esophageal epithelium in EoE patients expresses ISGs. Using organoid models, we demonstrate that IFN- $\gamma$  signaling disrupts epithelial proliferation, barrier function, and induces apoptosis, indicating that IFN- $\gamma$  has several detrimental effects on keratinocyte function in the esophagus which may have broad implications for infectious and inflammatory disorders of the esophagus. Our single cell analyses have identified a CD8<sup>+</sup> *IFNG*-expressing Trm cell cluster present during active and inactive EoE as a potential source of IFN- $\gamma$  in EoE. Additional work is needed to define the crosstalk between immune and epithelial cells to understand the extent to which interferon signaling may contribute to EoE pathogenesis.



## **Patient and public involvement:**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

## **Author contributions**

M.L., R.G., C.M.B., W.G.S., and M.A.R. planned and designed experiments. M.L., R.G., Z.M., T.T., J.B., M.C.C., C.M.B., and D.M.M performed experiments and discussed results. All authors contributed to the data analysis. A.B.M., W.E.S., M.A.R. were responsible for patient recruitment and study administration and support. M.L. wrote the first draft of the manuscript with input from M.A.R. All authors commented on and contributed to the final manuscript.

## **Acknowledgments**

We are grateful to the patients and their families for their participation in the studies. We acknowledge Azenta Life Sciences (Plainfield, NJ) for RNA sequencing of biopsies and esophageal epithelial organoid samples. We also acknowledge the University of Pennsylvania Perelman School of Medicine's Center for Molecular Studies in Digestive and Liver Diseases (Molecular Pathology and Imaging Core (research Resource Identifier RRID: SCR\_022420), as well as Children's Hospital of Philadelphia Flow Cytometry and Pathology Core Facilities for technical support. We thank Lauren Dolinski and Tokunbo Ashorobi for their efforts in recruiting patients to participate in this study and Joshua X. Wang and Dr. Takeo Hara for valuable technical guidance regarding organoid culture. We also thank members of the Center for Pediatric Eosinophilic Disorders for helpful discussions.

**Conflict of interest:** The authors have declared no conflict of interests.

**Funding Sources:** This project was funded via research grants NIH K08AI148456 (to MAR) and the AAAAI Foundation Faculty Development Award (to MAR). The Penn Molecular Pathology and Imaging Core is funded by NIH P30DK0050306. The content in this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

# References

1. Kelly KJ, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. *Gastroenterology*. 1995;109(5):1503–1512.
2. Spergel J, Aceves SS. Allergic components of eosinophilic esophagitis. *J Allergy Clin Immunol*. 2018;142(1):1–8.
3. Dellon ES, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. *N Engl J Med*. 2022;387(25):2317–2330.
4. Liacouras CA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. *J Allergy Clin Immunol*. 2011;128(1):3-20.e6; quiz 21–22.
5. Simon D, et al. Eosinophilic esophagitis is characterized by a non-IgE-mediated food hypersensitivity. *Allergy*. 2016;71(5):611–620.
6. Blanchard C, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. *J Allergy Clin Immunol*. 2011;127(1):208-217.e7.
7. Avlas S, et al. Epithelial cell-expressed type II IL-4 receptor mediates eosinophilic esophagitis. *Allergy*. 2023;78(2):464–476.
8. Morgan DM, et al. Clonally expanded, GPR15-expressing pathogenic effector T<sub>H</sub> 2 cells are associated with eosinophilic esophagitis. *Sci Immunol*. 2021;6(62):eabi5586.
9. Mishra A, et al. Critical role for adaptive T cell immunity in experimental eosinophilic esophagitis in mice. *J Leukoc Biol*. 2007;81(4):916–924.
10. Ruffner MA, et al. Conserved IFN Signature between Adult and Pediatric Eosinophilic Esophagitis. *J Immunol*. 2021;206(6):1361–1371.
11. Sayej WN, et al. Characterizing the inflammatory response in esophageal mucosal biopsies in children with eosinophilic esophagitis. *Clin Transl Immunol*. 2016;5(7):e88.
12. Jacobse J, et al. A synthesis and subgroup analysis of the eosinophilic esophagitis tissue transcriptome. *J Allergy Clin Immunol*. 2023;S0091-6749(23)01253–8.
13. Rebane A, et al. Mechanisms of IFN-γ–induced apoptosis of human skin keratinocytes in patients with atopic dermatitis. *J Allergy Clin Immunol*. 2012;129(5):1297–1306.
14. Soyka MB, et al. Defective epithelial barrier in chronic rhinosinusitis: The regulation of tight junctions by IFN-γ and IL-4. *J Allergy Clin Immunol*. 2012;130(5):1087-1096.e10.
15. Schuhmann D, et al. Interfering with interferon-γ signalling in intestinal epithelial cells: selective inhibition of apoptosis-maintained secretion of anti-inflammatory interleukin-18 binding protein. *Clin Exp Immunol*. 2011;163(1):65–76.
16. Smyth D, et al. Interferon-γ-induced increases in intestinal epithelial macromolecular permeability requires the Src kinase Fyn. *Lab Invest*. 2011;91(5):764–777.
17. Nava P, et al. Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. *Immunity*. 2010;32(3):392–402.

18. Barrett T, et al. NCBI GEO: archive for functional genomics data sets—update. *Nucleic Acids Res.* 2012;41(D1):D991–D995.
19. Edgar R. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* 2002;30(1):207–210.
20. Hao Y, et al. Integrated analysis of multimodal single-cell data. *Cell.* 2021;184(13):3573–3587.e29.
21. Stuart T, et al. Comprehensive Integration of Single-Cell Data. *Cell.* 2019;177(7):1888–1902.e21.
22. Butler A, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol.* 2018;36(5):411–420.
23. Satija R, et al. Spatial reconstruction of single-cell gene expression data. *Nat Biotechnol.* 2015;33(5):495–502.
24. Bunis DG, et al. dittoSeq: universal user-friendly single-cell and bulk RNA sequencing visualization toolkit. *Bioinformatics.* 2021;36(22–23):5535–5536.
25. Blighe K, Rana S, Lewis M (2023). EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling.
26. Dellon ES, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. *Gastroenterology.* 2018;155(4):1022–1033.e10.
27. Nakagawa H, et al. Modeling Epithelial Homeostasis and Reactive Epithelial Changes in Human and Murine Three-Dimensional Esophageal Organoids. *Curr Protoc Stem Cell Biol.* 2020;52(1):e106.
28. Harada H, et al. Telomerase induces immortalization of human esophageal keratinocytes without p16INK4a inactivation. *Mol Cancer Res MCR.* 2003;1(10):729–738.
29. Kasagi Y, et al. The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes. *Cell Mol Gastroenterol Hepatol.* 2018;5(3):333–352.
30. Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput Sequence Data [Internet]. <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>. Accessed March 29, 2023.
31. Ewels P, et al. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics.* 2016;32(19):3047–3048.
32. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics.* 2014;30(15):2114–2120.
33. Bray NL, et al. Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol.* 2016;34(5):525–527.
34. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* 2010;26(1):139–140.


35. Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015;43(7):e47–e47.
36. Wu T, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *The Innovation.* 2021;2(3):100141.
37. Yu G, et al. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. *OMICS J Integr Biol.* 2012;16(5):284–287.
38. Subramanian A, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci.* 2005;102(43):15545–15550.
39. Liberzon A, et al. Molecular signatures database (MSigDB) 3.0. *Bioinformatics.* 2011;27(12):1739–1740.
40. Uhlén M, et al. Tissue-based map of the human proteome. *Science.* 2015;347(6220):1260419.
41. Warnes G, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, Lumley T, Maechler M, Magnusson A, Moeller S, Schwartz M, Venables B (2022). *\_gplots: Various R Programming Tools for Plotting Data\_*.
42. Shannon P, et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. *Genome Res.* 2003;13(11):2498–2504.
43. H. Wickham. *ggplot2: Elegant Graphics for Data Analysis.* Springer-Verlag New York, 2016.
44. Ruffner MA, et al. Toll-like receptor 2 stimulation augments esophageal barrier integrity. *Allergy.* 2019;74(12):2449–2460.
45. Sherrill JD, et al. Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA sequencing. *Genes Immun.* 2014;15(6):361–369.
46. Blanchard C, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. *J Clin Invest.* 2006;116(2):536–547.
47. Bhattacharya B, et al. Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease. *Hum Pathol.* 2007;38(12):1744–1753.
48. Matoso A, et al. Correlation of ALOX15 expression with eosinophilic or reflux esophagitis in a cohort of pediatric patients with esophageal eosinophilia. *Hum Pathol.* 2014;45(6):1205–1212.
49. D'Mello RJ, et al. Identification and Characterization of Leucine-Rich Repeat Containing Protein 31 (LRRC31) in Eosinophilic Esophagitis. *J Allergy Clin Immunol.* 2015;135(2):AB173.
50. Dellon ES, et al. Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis. *Aliment Pharmacol Ther.* 2016;44(2):189–197.
51. Matoso A, et al. Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis. *Mod Pathol Off J U S Can Acad Pathol Inc.* 2013;26(5):665–676.
52. Rochman M, et al. Profound loss of esophageal tissue differentiation in patients with eosinophilic esophagitis. *J Allergy Clin Immunol.* 2017;140(3):738-749.e3.


53. The human proteome in esophagus - The Human Protein Atlas [Internet]. <https://www.proteinatlas.org/humanproteome/tissue/esophagus>. Accessed March 29, 2023.
54. Hara T, et al. CD73+ Epithelial Progenitor Cells That Contribute to Homeostasis and Renewal Are Depleted in Eosinophilic Esophagitis. *Cell Mol Gastroenterol Hepatol*. 2022;13(5):1449–1467.
55. Bruewer M, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. *J Immunol Baltim Md 1950*. 2003;171(11):6164–6172.
56. Utech M, et al. Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. *Mol Biol Cell*. 2005;16(10):5040–5052.
57. Bruewer M, et al. Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2005;19(8):923–933.
58. Sayoc-Becerra A, et al. The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction. *Inflamm Bowel Dis*. 2020;26(3):407–422.
59. Crawford CK, et al. Inflammatory cytokines directly disrupt the bovine intestinal epithelial barrier. *Sci Rep*. 2022;12(1):14578.
60. Bardenbacher M, et al. Permeability analyses and three dimensional imaging of interferon gamma-induced barrier disintegration in intestinal organoids. *Stem Cell Res*. 2019;35:101383.
61. Warners MJ, et al. Disease activity in eosinophilic esophagitis is associated with impaired esophageal barrier integrity. *Am J Physiol Gastrointest Liver Physiol*. 2017;313(3):G230–G238.
62. Simon D, et al. Evidence of an abnormal epithelial barrier in active, untreated and corticosteroid-treated eosinophilic esophagitis. *Allergy*. 2018;73(1):239–247.
63. Watson CJ, et al. Interferon- $\gamma$  selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores. *J Cell Sci*. 2005;118(22):5221–5230.
64. Mizutani Y, et al. Interferon- $\gamma$  downregulates tight junction function, which is rescued by interleukin-17A. *Exp Dermatol*. 2021;30(12):1754–1763.
65. Laky K, et al. Epithelial-intrinsic defects in TGF $\beta$ R signaling drive local allergic inflammation manifesting as eosinophilic esophagitis. *Sci Immunol*. 2023;8(79):eabp9940.
66. Gupta SK, et al. Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr*. 2006;42(1):22–26.
67. Mulder DJ, et al. Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis. *Am J Pathol*. 2011;178(2):744–753.
68. Wen T, et al. Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis. *J Clin Invest*. 2019;129(5):2014–2028.
69. Esaki H, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. *J Allergy Clin Immunol*. 2016;138(6):1639–1651.

70. Brunner PM, et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. *J Allergy Clin Immunol.* 2018;141(6):2094–2106.
71. Soyka MB, et al. Defective epithelial barrier in chronic rhinosinusitis: The regulation of tight junctions by IFN- $\gamma$  and IL-4. *J Allergy Clin Immunol.* 2012;130(5):1087-1096.e10.
72. Gan H, et al. Interferon- $\gamma$  promotes double-stranded RNA-induced TLR3-dependent apoptosis via upregulation of transcription factor Runx3 in airway epithelial cells. *Am J Physiol-Lung Cell Mol Physiol.* 2016;311(6):L1101–L1112.
73. Zheng T, et al. Role of Cathepsin S-Dependent Epithelial Cell Apoptosis in IFN- $\gamma$ -Induced Alveolar Remodeling and Pulmonary Emphysema. *J Immunol.* 2005;174(12):8106–8115.
74. Woznicki JA, et al. Human BCL-G regulates secretion of inflammatory chemokines but is dispensable for induction of apoptosis by IFN- $\gamma$  and TNF- $\alpha$  in intestinal epithelial cells. *Cell Death Dis.* 2020;11(1):68.
75. Wang F, et al. Interferon- $\gamma$  and Tumor Necrosis Factor- $\alpha$  Synergize to Induce Intestinal Epithelial Barrier Dysfunction by Up-Regulating Myosin Light Chain Kinase Expression. *Am J Pathol.* 2005;166(2):409–419.
76. Schuhmann D, et al. Interfering with interferon- $\gamma$  signalling in intestinal epithelial cells: selective inhibition of apoptosis-maintained secretion of anti-inflammatory interleukin-18 binding protein. *Clin Exp Immunol.* 2010;163(1):65–76.
77. Trautmann A, et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. *J Allergy Clin Immunol.* 2001;108(5):839–846.
78. Simon D, et al. Epidermal caspase-3 cleavage associated with interferon-gamma-expressing lymphocytes in acute atopic dermatitis lesions. *Exp Dermatol.* 2006;15(6):441–446.
79. Reilly EC, et al. TRM integrins CD103 and CD49a differentially support adherence and motility after resolution of influenza virus infection. *Proc Natl Acad Sci U S A.* 2020;117(22):12306–12314.
80. Yenyuwadee S, et al. The evolving role of tissue-resident memory T cells in infections and cancer. *Sci Adv.* 2022;8(33):eabo5871.
81. Dunn JLM, et al. Bidirectional crosstalk between eosinophils and esophageal epithelial cells regulates inflammatory and remodeling processes. *Mucosal Immunol.* 2021;14(5):1133–1143.



## Figures:






**Figure 2. IFN $\gamma$ -STAT1 stimulation induces changes in the morphological and functional features of human esophageal epithelial organoids.** (A) Flow cytometry analysis of IFN- $\alpha$  and IFN- $\gamma$  receptor subunits on EPC2-hTERT cells; plot showing the mean fluorescence intensity for each condition. n=5 replicates. (B) Time course of STAT1 and STAT2 phosphorylation by western blot in EPC2-hTERT cells, representative of 3 experiments. (C) Schematic depicting the 3D organoid epithelial culture model. The culture encompasses days 1 to 11, recapitulating the intricate architecture, proliferation,




and differentiation gradient observed in the human esophageal epithelium. External stimuli are introduced into the media from days 7 to 9, capturing the responsive changes associated with esophageal disease conditions. (D) The organoid formation rate was determined on day 11 and calculated as the total number of organoids divided by the total number of seeded cells. (n=3 organoids per group, mean  $\pm$  SD). (E) Organoid size was reported as the mean diameter ( $\mu\text{m}$ ) at day 11 (n=10 organoids per group, mean  $\pm$  SD). (F) Representative images of H&E staining of human esophageal epithelial 3D organoids harvested on day 11. Scale bar = 150  $\mu\text{m}$ . (G) Basaloid content in organoids on day 11 was determined as the percentage of the total height of basaloid cell layers divided by the overall organoid diameter (n=10 organoids per group, mean  $\pm$  SD, \*\*\* p-value < 0.001, \*\* p-value < 0.01, and \* p-value < 0.05). (H) Immunohistochemistry staining for pSTAT-1, Ki67, and IVL in organoids treated with IFN- $\alpha$  or IFN- $\gamma$  at day 11. The corresponding IHC images can be found in Figure S8. The graphs show the quantification of staining intensity (n=10 organoids per group, mean  $\pm$  SD, \*\*\* p-value < 0.001, \*\* p-value < 0.01, and \* p-value < 0.05).




**Figure 3. IFN- $\gamma$  treatment *in vitro* replicates the *in vivo* IFN- $\gamma$  response and changes the expression of a subset of genes relevant to esophageal biology.** (A) PCA plot showing separation between IFN- $\gamma$  treated organoids and IFN- $\alpha$  treated and unstimulated organoids based on gene expression profiles using the first three principal components that account for most of the variation in the dataset. (B) Volcano plot showing differential gene expression in IFN- $\gamma$  treated organoids versus unstimulated organoid cultures. (C) The ridge plot shows the running enrichment score of 14 pathways with positive enrichment scores and 10 pathways with negative enrichment scores in IFN- $\gamma$  treated organoids and  $p.adjust < 0.05$ . (D) Venn diagram illustrating the overlap of upregulated

(red) and downregulated (blue) genes shared between esophagus-specific genes and IFN- $\gamma$  treated organoids.




**Figure 4. IFN- $\gamma$  treatment disrupts epithelial barrier function in esophageal epithelium.** (A) Hierarchical clustering based on the leading edge of the positively enriched pathway, HALLMARK\_APICAL\_JUNCTION; heatmap showing gene expression levels across IFN- $\gamma$  and IFN- $\alpha$  treated and unstimulated organoids. (B) IHC of tight junction proteins, Claudin 1 and Occludin in 3D organoids derived from EPC2-hTERT cells treated with IFN- $\alpha$  and IFN- $\gamma$ . (C) Schematic depicting the ALI (Air-Liquid Interface) epithelial culture model. The culture spans days 1 to 7, facilitating proliferation

and initial differentiation, followed by days 7 to 10, which support terminal differentiation. External stimuli are introduced into the basolateral media chamber from days 10 to 14, enabling the evaluation of their impact on epithelial barrier function. (D) Transepithelial electrical resistance (TEER) was measured on day 14 and calculated as net resistance  $\times$  membrane area (0.33cm<sup>2</sup> for 24-well Millicell inserts), and only samples with TEER > 200  $\Omega$ \*cm<sup>2</sup> on day 10 were used for stimulation experiments. (n=6 wells per group, mean  $\pm$  SD, \* p-value < 0.05). (E) Basolateral translocation of 70kDa FITC-dextran across ALI membranes to assess the permeability upon IFN treatment (n=6 wells per group, mean  $\pm$  SD, \* p-value < 0.05).



**Figure 5. IFN- $\gamma$  treatment potentiates cytotoxicity in esophageal epithelium.** (A) Hierarchical clustering based on the leading edge of the positively enriched pathway, HALLMARK\_APOPTOSIS; heatmap showing gene expression levels across IFN- $\gamma$  and IFN- $\alpha$  treated and unstimulated organoids. (B) Expression of apoptotic markers, caspase-3 and caspase-8 in EPC2-hTERT cells treated with IFN- $\alpha$  and IFN- $\gamma$  (n=12 replicates, mean  $\pm$  SD, \*\*\* p-value < 0.001). (C) MTT assay to evaluate the cell viability upon IFN treatment (n=12 replicates, mean  $\pm$  SD, \*\*\* p-value < 0.001). (D) Representative IHC for cleaved caspase-3 in the esophageal epithelium of EoE active and control subjects. Scale bar = 50  $\mu$ m.



**Figure 6: Single-cell analysis reveals activated CD8+ T cells as the main source of IFN- $\gamma$  and upregulated IFN- $\gamma$  receptors in eosinophils during active disease.** (A) Dot plot of IFN signaling genes for each cell type in the esophagus displaying average expression and frequency of expression for each gene (B) Scaled expression and frequency of *IFNG* in esophageal T cells separated by disease state. The abbreviations used: Trm = tissue resident memory and peTh2 = pathogenic effector Th2.

**Table 1. Demographics of patient cohort.**

Characteristics	ACTIVE (N = 10)	CONTROL (N = 13)
Age (years)	10 (4.5-12.0)	14 (11-17)
Gender (male)	8 (80%)	7 (53.85%)
Eos/HPF	87.5 (32.5-100)	0 (0-0)
Swallowed Steroids (Y)	3 (30%)	0 (0%)
PPI (Y)	4 (40%)	9 (96.23%)
Diet (Restricted)	8 (80%)	5 (38.46%)
Race (White)	5 (50%)	13 (100%)
Ethnicity (Hispanic or Latino)	2 (20%)	0 (0%)

Data are given as N (%) or median (interquartile range [IQR]) unless otherwise stated. IQR, interquartile range; HPF, high powered field; PPI, proton pump inhibitor.